NCT05519670View on ClinicalTrials.gov

A Phase 1b/2 Trial Evaluating Safety and Efficacy of CAPecitabine in Combination With Ni-rapaRIb in HER2-negative Advanced Breast canCEr

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

72

Participants

Timeline

Start Date

March 31, 2023

Primary Completion Date

September 30, 2027

Study Completion Date

December 31, 2027

Conditions

Breast Cancer

Interventions

DRUG

Niraparib Oral Product

Niraparib + capecitabine treatment

Sponsors

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

GlaxoSmithKline

INDUSTRY

lead

Institut Paoli-Calmettes

OTHER